U.S. Food and Drug Administration

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.

Small Business Assistance Financial Assistance and Incentives for Research and Development of New Drug/Biologic Products Ron Wilson, Director of Small Business Assistance Center for Drug Development and Research, FDA Ronald.Wilson@fda.hhs.gov 1

Small Business Assistance Website http://www.fda.gov/drugs/developmentapprovalprocess/small BusinessAssistance/default.htm Information for Clinical Investigators New Drug Development and Review Process Orphan Drug Program Generic Drug Review Process Over-the-Counter Drug Product Review Process Post Drug Approval Activities Drug Registration and Listing Organization, Contact and Meeting Information FDA Related Laws, Regulations, and Guidances Economic Assistance and Incentives for Drug Development Economic Assistance, Pre-Approval Economic Incentives Post-Approval 2

Financial Assistance Pre-Approval and Financial Incentives Post-Approval Financial Assistance Pre-Approval Orphan Drug Program PDUFA Charging for Investigational Drugs Grants Financial Incentives Post-Approval Orphan Drug Products Exclusivity New Chemical Entity Exclusivity (Hatch/Waxman) New Clinical Investigation Exclusivity (Hatch/Waxman) Pediatric Exclusivity 180-Day Generic Drug Exclusivity Patent Term Extension 3

Financial Assistance Pre- Approval Orphan Drug Products PDUFA Charging for Investigational Drugs Grants 4

Orphan Drug Program Orphan Drug Program Identifies orphan drug products Facilitates their development in the treatment of rare diseases* and conditions *Rare disease means any disease or condition which affects less than 200,000 persons in the U.S http://www.fda.gov/forindustry/developingproductsf orrarediseasesconditions/default.htm 5

Orphan Drug Program http://www.fda.gov/orphan/index.htm Assistance Provided for Orphan Drug Designation Tax credits Research grants Waiver of PDUFA application and supplement fees Exclusivity 6

Prescription Drug User Fee Act (PDUFA) Enacted in 1992 Authorizes FDA to collect fees from companies that produce certain human drug and biological products 7

PDUFA Fees for drugs and biologics Three types of users fees--application Fees, Establishment Fees, and Product Fees PDUFA Q&A for small businesses http://www.fda.gov/drugs/developmentap provalprocess/smallbusinessassistance/u cm069943.htm 8

PDUFA Financial Provisions of PDUFA Waivers Reductions Refunds 9

PDUFA Waivers Waiver of the application fee for the first human drug application that a small business (500 or less employees) or its affiliate submits for review is waived Waiver may be granted to any business for one or more fees Waiver may be granted if the assessment of the user fees would present a significant barrier to innovation due to limited resources or circumstances 10

PDUFA Reductions/Refunds Reduction or refund of fees may be granted for an application or supplement that is refused for filing or withdrawn before or after filing 11

PDUFA Procedures for Requesting Waiver,Reduction, or Refund of Fee To qualify, a written request must be submitted not later than 180 days after the fee is due See PDUFA Q&A for specific information on how/where to submit a request 12

Charging for Investigational Drugs 21CFR 312.7(d) permits sale of an investigational drug or biological product Certain requirements have to be met before charging is permitted http://www.fda.gov/drugs/developmentap provalprocess/howdrugsaredevelopedand Approved/ApprovalApplications/Investigati onalnewdrugindapplication/ucm172492.ht m 13

Grants Solicited grant applications Unsolicited grant applications Small Innovation Research Program Small Business Technology Program Grants & Funding Opportunities at NIH 14

Grants Solicited Grant Applications FDA solicits competitive applications through requests for applications (RFA) RFA s are published in the federal register and other appropriate publications. A list of RFA s can be found on www.grants.gov http://www.fda.gov/aboutfda/business/ucm119 348.htm 15

Grants Unsolicited Grant Applications Unsolicited grant applications are those not submitted in response to a published request for application (RFA) All unsolicited applications seeking FDA support should be submitted to the Center for Scientific Review (CSR) at the NIH http://cms.csr.nih.gov 16

Grants Small Business Innovation Research Program Requirement for Federal agencies with extramural budgets over $100 million Set-aside program for small businesses to engage in federal R&D Potential for commercialization and public benefit using an annual set-aside of 2.5% 17

Grants Small Business Innovation Program (Cont d) Small business is defined as having 500 or fewer employees FDA and NIH have SBIR programs FY 2008--FDA ($562,000 thousand) and NIH ($600M) http://grants.nih.gov/grants/funding/sbir.htm 18

Commercialization Assistance Program (CAP) NIH s SBIR CAP Program is a nationwide program funded by NIH for NIH SBIR Phase II awardees 10 month program designed to help some of the nation s most promising small life science and healthcare companies develop their businesses http://grants.nih.gov/grants/funding/cap/index. htm 19

Grants Small Business Technology Transfer Program (STTR) Requirement for Federal agencies with extramural budgets over $1 billion to administer STTR programs Using an annual set-aside of 0.3% for small businesses with 500 or fewer employees 20

Grants STTR Program (Cont d) Objective similar to SBIR Unique feature is the requirement for the small business applicant organization to formally collaborate with a research institution At least 40% of the STTR research project is to be conducted by the small business and at least 30% of the work is to be conducted by the research institution 21

GRANTS SBIR and STTR Program Structure Phase l: Establishes technical merit and feasibility of the proposed R/R&D efforts Phase ll: Continues R&D efforts initiated in phase I with award of additional support Phase III: Pursue with non-sbir and STTR funds the commercialization of objectives resulting from phase I/II R/R&D activities 22

SBIR/STTR Conference Annual NIH SBIR/STTR conference A two-day annual conference for small businesses conducting innovative health-related research htp://nbdc.unomaha.edu/sbir/nihconference/home.htm 23

Grants and Funding Opportunities at NIH Grants Research Contracts NIH Guide for Grants and Contracts Research Training Opportunities http://grants.nih.gov/grants/oer.htm 24

Financial Incentives Post- Approval Orphan Drug Products Exclusivity New Chemical Entity Exclusivity (Hatch- Waxman) New Clinical investigation Exclusivity (Hatch- Waxman Exclusivity) Pediatric Exclusivity 180-day Generic Drug Exclusivity Patent Term Extension 25

Exclusivity Exclusivity generally bars FDA approval or acceptance of certain applications for competing drugs. Exclusivity runs from date of approval. Concurrent with protection (if any), except for pediatric exclusivity which attaches to an existing exclusivity or patent period. 26

Hatch/Waxman 5 Year Exclusivity Purpose was to encourage research and development of new drugs 5-year period of exclusivity is granted to new drug products containing chemical entities never previously approved by FDA either alone or in combination No 505(b)(2) application or ANDA may be submitted during the 5-year exclusivity period Full new drug applications under 505(b)(1) and 505(b)(2) can receive the 5 years of exclusivity http://www.fda.gov/drugs/developmentapprovalp 27 rocess/smallbusinessassistance/ucm069962.htm

Hatch/Waxman 3 Year Exclusivity A 3-year period of exclusivity is granted for a change in an approved drug product. Approval requires new clinical investigations (other than bioavailability studies) Examples of the changes in an approved drug product that affect its active ingredient(s) are new indication, strength, dosage form, route of administration For 3 years FDA may not approve an ANDA (505)(j) or 505(b)(2) for the protected change http://www.fda.gov/downloads/drugs/guidancecomplianc eregulatoryinformation/guidances/ucm079345.pdf 28

Pediatric Exclusivity Six months exclusivity as an incentive to sponsors to conduct more studies of the use of drug in pediatric populations Attaches to the END of all existing marketing exclusivity and patent periods. Hatch/Waxman-exclusivity, orphan drug exclusivity, and patent periods run concurrently Only drug products subject to section 505 of the Food, Drug and Cosmetic Act are eligible for pediatric exclusivity Pediatric Drug Development http://www.fda.gov/drugs/developmentapprovalprocess/dev elopmentresources/ucm049867.htm 29

Generic Drug Exclusivity (180-day Exclusivity) 180 days of exclusivity for first ANDA applicant to file a complete application, successfully challenge listed patent and receive FDA approval The agency has proposed new regulations in the implementation of the 180-day exclusivity. Have not been published. http://www.fda.gov/drugs/developmentapprovalproces s/smallbusinessassistance/ucm069964.htm 30

Patent Term Extension Up to 5 years of patent extension for creating innovative products that benefit the public. Includes most products regulated by FDA including drugs and biologic Must be the first commercial marketing or use of the product under the provision of the law which such regulatory review occurred FDA assists patent trademark office (PTO) in determining a products eligibility for patent extension. PTO is responsible for determining the period of patent extension http://www.fda.gov/drugs/developmentapprovalprocess/sm allbusinessassistance/ucm069959.htm 31

Other Federal Assistance Small Business Administration federal grant resources http://www.sba.gov www.grants.gov The Catalog of Federal Domestic Assistance www.gsa.gov/fdac/ NIAID Biodefense Research www.niaid.nih.gov 32

Hollings Manufacturing Extension Partnership (MEP) Hollings Manufacturing Extension Partnership with NIST provides technical and business assistance to smaller manufacturers. MEP is a national network with hundreds of specialists who understand the needs of manufacturers http://www.mep.nist.gov/ 33

SCORE The SCORE Association (Service Corps of Retired Executives) is a resource partner of the SBA dedicated to entrepreneur education and the formation, growth and success of small businesses nationwide. There are more than 10,500 SCORE volunteers in 374 chapters operating in over 800 locations who assist small businesses with business counseling and training. SCORE also operates an active online counseling initiative. http://www.score.org/index.html 34

Small Business Assistance ListServ What's new for small pharmaceutical businesses: Receive email notification of new information (federal register notices, guidances, workshops, etc.) Small Business Assistance Website provides the link-- http://www.fda.gov/drugs/developmentapprovalprocess/ SmallBusinessAssistance/default.htm Complete the listserv form. 35